Regentis Biomaterials received CE Mark approval for its GelrinC® biodegradable implant, made with denatured human fibrinogen, for the treatment of articular knee cartilage defects. This expands upon the existing CE Mark that is based upon denatured bovine-sourced fibrinogen.
Regentis is conducting an FDA-approved Phase III pivotal multi-site clinical trial on GelrinC in the U.S. and Europe to support a premarket approval application.
Regentis Biomaterials received CE Mark approval for its GelrinC® biodegradable implant, made with denatured human fibrinogen, for the treatment of articular knee cartilage defects. This expands upon the existing CE Mark that is based upon denatured bovine-sourced fibrinogen.
Regentis is conducting an FDA-approved Phase III pivotal...
Regentis Biomaterials received CE Mark approval for its GelrinC® biodegradable implant, made with denatured human fibrinogen, for the treatment of articular knee cartilage defects. This expands upon the existing CE Mark that is based upon denatured bovine-sourced fibrinogen.
Regentis is conducting an FDA-approved Phase III pivotal multi-site clinical trial on GelrinC in the U.S. and Europe to support a premarket approval application.
Copy to clipboard 
